Sphera Funds Management LTD. boosted its holdings in Neos Therapeutics Inc (NASDAQ:NEOS) by 136.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 831,697 shares of the company’s stock after acquiring an additional 479,555 shares during the quarter. Sphera Funds Management LTD. owned about 2.80% of Neos Therapeutics worth $4,034,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in NEOS. Trexquant Investment LP purchased a new position in Neos Therapeutics in the second quarter worth $131,000. Schwab Charles Investment Management Inc. raised its position in Neos Therapeutics by 28.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 56,200 shares of the company’s stock worth $352,000 after acquiring an additional 12,500 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Neos Therapeutics in the second quarter valued at $469,000. Millennium Management LLC purchased a new position in shares of Neos Therapeutics in the first quarter valued at $519,000. Finally, Bridgeway Capital Management Inc. increased its position in shares of Neos Therapeutics by 41.6% in the third quarter. Bridgeway Capital Management Inc. now owns 170,100 shares of the company’s stock valued at $825,000 after buying an additional 50,000 shares in the last quarter. Hedge funds and other institutional investors own 45.12% of the company’s stock.
A number of research analysts have recently weighed in on NEOS shares. ValuEngine upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, September 24th. JMP Securities dropped their price target on Neos Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a research report on Monday, November 12th. Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 price target on shares of Neos Therapeutics in a research report on Friday, November 9th. Finally, Wells Fargo & Co dropped their price target on Neos Therapeutics from $11.00 to $6.00 and set an “outperform” rating for the company in a research report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. Neos Therapeutics has a consensus rating of “Hold” and a consensus target price of $12.00.
In other news, Director Alan L. Heller purchased 43,478 shares of the company’s stock in a transaction dated Thursday, November 8th. The stock was acquired at an average price of $2.30 per share, for a total transaction of $99,999.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.40% of the company’s stock.
Shares of NEOS stock opened at $2.00 on Friday. Neos Therapeutics Inc has a fifty-two week low of $1.65 and a fifty-two week high of $11.69. The firm has a market capitalization of $60.24 million, a PE ratio of -0.75 and a beta of 0.34.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Friday, November 9th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.03). Neos Therapeutics had a negative net margin of 133.46% and a negative return on equity of 586.25%. The firm had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $14.80 million. As a group, sell-side analysts forecast that Neos Therapeutics Inc will post -1.71 EPS for the current year.
Neos Therapeutics Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
See Also: Reverse Stock Split
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.